AR041426A1 - Derivados de azol-pirimidina condensados; uso del compuesto para la preparacion de medicamentos - Google Patents
Derivados de azol-pirimidina condensados; uso del compuesto para la preparacion de medicamentosInfo
- Publication number
- AR041426A1 AR041426A1 ARP030103542A ARP030103542A AR041426A1 AR 041426 A1 AR041426 A1 AR 041426A1 AR P030103542 A ARP030103542 A AR P030103542A AR P030103542 A ARP030103542 A AR P030103542A AR 041426 A1 AR041426 A1 AR 041426A1
- Authority
- AR
- Argentina
- Prior art keywords
- amino
- alkyl
- optionally substituted
- aminocarbonyl
- halogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Los presentes compuestos son derivados de azolpirimidina condensados, los cuales presentan una mayor potencia para la inhibición de la fosfatidilinositol-3-quinasa (PI3K), especialmente para la inhibición de la PI3K-gama y pueden usarse para la profilaxis y tratamiento de enfermedades asociadas con la actividad de PI3K y particularmente con la actividad de PI3K-gama. Más específicamente, éstos derivados de azol son los ingredientes activos de medicamentos útiles para el tratamiento y profilaxis de las siguientes enfermedades: trastornos inflamatorios e inmunorreguladores tales como asma, dermatitis, atópica, rinitis, enfermedades alérgicas, enfermedad pulmonar obstructiva crónica (COPD), choque séptico, enfermedades de las articulaciones, patologías autoinmunes tales como artritis reumatoide, y enfermedad de Graves, cáncer, trastornos de contractilidad del miocardio, insuficiencia cardíaca, tromboembolia, isquemia y aterosclerosis. Estos medicamentos también son útiles para la hipertensión pulmonar, insuficiencia renal, hipertrofia cardíaca así como trastornos neurodegenerativos tales como enfermedad de Parkinson, enfermedad de Alzheimer, diabetes e isquemia focal, ya que las enfermedades también están relacionadas con la actividad de PI3K en un ser humano o animal. Reivindicación 1: Un derivado de azolpirimidina condensado de fórmula (1), su forma tautomérica o estereoisomérica, o una sal del mismo, donde: X representa CR5R6 o NH; Y1 representa CR3 o N; el enlace químico entre Y2 puntos línea Y3 representa un enlace sencillo o un doble enlace, con la condición de que cuando Y2 puntos línea Y3 representa un doble enlace; Y2 e Y3 representa independientemente CR4 o N, y cuando Y2 puntos línea Y3 representa un enlace sencillo, Y2 e Y3 representa independientemente CR3R4 o NR4; Z1, Z2, Z3 y Z4 representan independientemente CH, CR2 o N; R1 representa arilo que tiene opcionalmente de 1 a 3 sustituyentes seleccionados entre R11, cicloalquilo C3-8 que tiene opcionalmente de 1 a 3 sustituyentes seleccionados entre R11, alquilo C1-6 opcionalmente sustituido con arilo, heteroarilo, alcoxiarilo C1-6, ariloxi, heteroariloxi o uno o más halógenos, alcoxi C1-6 opcionalmente sustituido con carboxi, arilo, heteroarilo, alcoxiarilo C1-6, ariloxi, heteroariloxi o uno o más halógenos, o un anillo heterocíclico mono- o bi-cíclico de 3 a 15 miembros que está saturado o insaturado, que tiene opcionalmente de 1 a 3 sustituyentes seleccionados entre R11, y contiene de 1 a 3 heteroátomos seleccionados entre el grupo compuesto por N, O y S; donde R11 representa halógeno, nitro, hidroxi, ciano, carboxi, amino, N-(alquil C1-6)amino, N-(hidroxialquil C1-6)amino, N,N-di(alquil C1-6)amino, N-(acil C1-6)amino, N-(formil)-N-(alquil C1-6)amino, N-(alcanosulfonil C1-6)amino, N-(carboxialquil C1-6)-N-(alquil C1-6)amino, N-(alcoxicarbonil C1-6)amino, N-[N,N-di(alquil C1-6)aminometileno]amino, N-[N,N-di(alquil C1-6)amino(alquil C1-6)metileno]amino, N-[N,N-di(alquil C1-6)aminoalquenil C2-6]amino, aminocarbonilo, N-(alquil C1-6)aminocarbonilo, N,N-di(alquil C1-6)aminocarbonilo, cicloalquilo C3-8, alquiltio C1-6, alcanosulfonilo C1-6, sulfamoilo, alcoxicarbonilo C1-6, N-arilamino donde dicho resto arilo tiene opcionalmente de 1 a 3 sustituyentes seleccionados entre R101, N-(arilalquil C1-6)amino, donde dicho reto arilo tiene opcionalmente de 1 a 3 sustituyentes seleccionados entre R101, arilalcoxi(C1-6)-carbonilo donde dicho resto arilo tiene opcionalmente de 1 a 3 sustituyentes seleccionados entre R101, alquilo C1-6 opcionalmente sustituido cono mono-, di- o tri-halógeno, amino, N-(alquil C1-6)amino o N,N-di(alquil C1-6)amino, alcoxi C1-6 opcionalmente sustituido cono mono-, di- o tri-halógeno, N-(alquil C1-6)sulfonamida o N-(aril)sulfonamida, o un anillo saturado o insaturado de 5 a 7 miembros que tiene de 1 a 3 heteroátomos seleccionados entre el grupo compuesto por O, S y N, y que tiene opcionalmente de 1 a 3 sustituyentes seleccionados entre R101; donde R01 representa halógeno, carboxi, amino, N-(alquil C1-6)amino, N,N-di(alquil C1-6)amino, aminocarbonilo, N-(alquil C1-6)aminocarbonilo, N,N-di(alquil C1-6)aminocarbonilo, piridilo, alquilo C1-6 opcionalmente sustituido con ciano o mono- di.- o tri-halógeno, y alcoxi C1-6 opcionalmente sustituido con ciano, carboxi, amino, N-(alquil C1-6)amino, N,N-di(alquil C1-6)amino, aminocarbonilo, N-(alquil C1-6)aminocarbonilo, N,N-di(alquil C1-6)aminocarbonilo o mono-, di- o tri-halógeno; R2 representa hidroxi, halógeno, nitro, ciano, amino, N-(alquil C1-6)amino, N,N-di(alquil C1-6)amino, N-(hidroxialquil C1-6)amino, N-(hidroxialquil C1-6)-N-(alquil C1-6)amino, aciloxi C1-6, aminoaciloxi C1-6, alquenilo C2-6, arilo, un anillo heterocíclico saturado o insaturado de 5-7 miembros que tiene de 1 a 3 heteroátomos seleccionados entre el grupo compuesto por O, S y N, y opcionalmente sustituido con hidroxi, alquilo c1-6, alcoxi C1-6, oxo, amino, aminoalquilo C1-6, N-(alquil C1-6)amino, N,N-di(alquil C1-6)amino, N-(acil C1-6)amino, N-(alquil c1-6)carbonilamino, fenilo, fenilalquilo C1-6, carboxi, alcoxicarbonilo C1-6, aminocarbonilo, N-(alquil C1-6)aminocarbonilo o N,N-di(alquil C1-6)amino, -C(O)-R20; donde R20 representa alquilo C1-6, alcoxi C1-6, amino, N-(alquil C1-6)amino, N,N-di(alquil C1-6)amino, N-(acil C1-6)amino o un anillo heterocíclico saturado o insaturado de 5-7 miembros que tiene de 1 a 3 heteroátomos seleccionados entre el grupo compuesto por O, S y N, y opcionalmente sustituido con alquilo C1-6, alcoxi C1-6, oxo, amino N-(alquil C1-6)amino, N,N-di(alquil C1-6)amino, N-(acil C1-6)amino, fenilo o bencilo, alquilo C1-6 opcionalmente sustituido con R21 o alcoxi C1-6 opcionalmente sustituido con R21; donde R21 representa ciano, mono-, di- o tri-halógeno, hidroxi, amino, N-(alquil C1-6)amino, N,N-di(alquil C1-6)amino, N-(hidroxialquil C1-6)amino, N-(halofenilalquil C1-6)amino, aminoalquilenilo C2-6, alcoxi C1-6, hidroxialcoxi C1-6,-C(O)-R21, -NHC(O)-R201, cicloalquilo C3-8, isoindonilo, ftalimidilo 2-oxo-1,3-oxazolidinilo, arilo o un anillo heterocíclico saturado o insaturado de 5 ó 6 miembros que tiene de 1 a 4 heteroátomos seleccionados entre el grupo compuesto por O, S o N opcionalmente sustituido con hidroxi, alquilo C1-6, alcoxi C1-6, alcoxicarbonilo C1-6, hidroxialcoxi C1-6, oxo, amino, aminoalquilo C1-6, N-(alquil C1-6)amino, N,N-di(alquil C1-6)amino, N-(acil C1-6)amino o bencilo; donde R201 representa hidroxi, amino, N-(alquil C1-6)amino, N,N-(alquil C1-6)amino, N-(halofenilalquil C1-6)amino, alquilo C1-6, aminoalquilo C1-6, aminoalquilenilo C2-6, alcoxi C1-6, un anillo heterocíclico saturado o insaturado de 5 ó 6 miembros que tiene de 1 a 4 heteroátomos seleccionados entre el grupo compuesto por O, S y N opcionalmente sustituidos con hidroxi, alquilo C1-6, alcoxi C1-6, alcoxicarbonilo C1-6, hidroxialcoxi c1-6, oxo, amino, N-(alquil C1-6)amino, N,N-di(alquil C1-6)amino, N-(acil C1-6)amino o bencilo; R3 representa hidrógeno, halógeno, aminocarbonilo o alquilo C1-6 opcionalmente sustituido con arilalcoxi C1-6 o mono-, di- o tri-halógeno; R4 representa hidrógeno o alquilo C1-6; R5 representa hidrógeno o alquilo C1-6; y R6 representa halógeno, hidrógeno o alquilo C1-6.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02021861 | 2002-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR041426A1 true AR041426A1 (es) | 2005-05-18 |
Family
ID=32039115
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP030103542A AR041426A1 (es) | 2002-09-30 | 2003-09-29 | Derivados de azol-pirimidina condensados; uso del compuesto para la preparacion de medicamentos |
ARP090102458A AR072458A2 (es) | 2002-09-30 | 2009-07-01 | Derivados de azol-pirimidina condensados, composiciones farmaceuticas que los contienen y su uso para inhibir la actividad pi3k-? |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090102458A AR072458A2 (es) | 2002-09-30 | 2009-07-01 | Derivados de azol-pirimidina condensados, composiciones farmaceuticas que los contienen y su uso para inhibir la actividad pi3k-? |
Country Status (33)
Country | Link |
---|---|
US (2) | US7511041B2 (es) |
EP (2) | EP1549652B1 (es) |
JP (1) | JP4790266B2 (es) |
KR (1) | KR101059652B1 (es) |
CN (1) | CN100384846C (es) |
AR (2) | AR041426A1 (es) |
AT (2) | ATE411996T1 (es) |
AU (1) | AU2003293310B2 (es) |
BR (1) | BRPI0314830B8 (es) |
CA (1) | CA2499134C (es) |
CY (2) | CY1109790T1 (es) |
DE (1) | DE60324296D1 (es) |
DK (2) | DK1549652T3 (es) |
EC (2) | ECSP055768A (es) |
ES (2) | ES2312843T3 (es) |
HK (1) | HK1084393A1 (es) |
HR (2) | HRP20050375B1 (es) |
IL (1) | IL166855A (es) |
MA (1) | MA27483A1 (es) |
MX (1) | MXPA05001808A (es) |
MY (1) | MY140756A (es) |
NO (1) | NO331457B1 (es) |
NZ (1) | NZ539062A (es) |
PE (1) | PE20050089A1 (es) |
PL (1) | PL226562B1 (es) |
PT (2) | PT2042504E (es) |
RU (1) | RU2326881C9 (es) |
SI (2) | SI2042504T1 (es) |
TW (1) | TWI327570B (es) |
UA (1) | UA82205C2 (es) |
UY (1) | UY28001A1 (es) |
WO (1) | WO2004029055A1 (es) |
ZA (1) | ZA200503306B (es) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
ZA200706586B (en) | 2003-08-29 | 2008-07-30 | Mitsui Chemicals Inc | Insecticide for agricultural or horticultural use and method of use thereof |
CN101031569B (zh) | 2004-05-13 | 2011-06-22 | 艾科斯有限公司 | 作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮 |
BRPI0516557A (pt) | 2004-10-07 | 2008-09-09 | Boehringer Ingelheim Int | pi3 cinases |
WO2006040645A1 (en) * | 2004-10-11 | 2006-04-20 | Ranbaxy Laboratories Limited | N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma |
EP3770278A1 (en) | 2005-04-14 | 2021-01-27 | The Trustees of Boston University | Diagnostic for lung disorders using class prediction |
NZ565470A (en) * | 2005-07-29 | 2010-11-26 | 4Sc Ag | Novel heterocyclic NF-kB inhibitors |
EP2605018A1 (en) | 2006-03-09 | 2013-06-19 | The Trustees of the Boston University | Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells |
US7691868B2 (en) | 2006-04-06 | 2010-04-06 | Boehringer Ingelheim International Gmbh | Thiazolyl-dihydro-quinazoline |
US7517995B2 (en) * | 2006-04-06 | 2009-04-14 | Boehringer Ingelheim International Gmbh | Thiazolyl-dihydro-cyclopentapyrazole |
MX2008013584A (es) * | 2006-04-26 | 2009-03-23 | Genentech Inc | Compuestos farmaceuticos. |
WO2008064244A2 (en) * | 2006-11-20 | 2008-05-29 | The Trustees Of Columbia University In The City Of New York | Phosphoinositide modulation for the treatment of neurodegenerative diseases |
AR064106A1 (es) | 2006-12-05 | 2009-03-11 | Bayer Schering Pharma Ag | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis |
EP1953163A1 (en) * | 2007-02-01 | 2008-08-06 | Boehringer Ingelheim Pharma GmbH & Co. KG | Pteridinone derivatives as PI3-kinases inhibitors |
WO2008148023A2 (en) * | 2007-05-23 | 2008-12-04 | Medical College Of Georgia Research Institute, Inc. | Compositions and methods for treating neurological disorders |
EP2217590A4 (en) * | 2007-09-17 | 2011-12-14 | Glaxosmithkline Llc | Pyridopyrimidine derivatives as PI3-kinase inhibitors |
US20090186951A1 (en) | 2007-09-19 | 2009-07-23 | Brody Jerome S | Identification of novel pathways for drug development for lung disease |
WO2009091550A2 (en) * | 2008-01-14 | 2009-07-23 | Bayer Healthcare Llc | Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis |
JP5581219B2 (ja) | 2008-01-25 | 2014-08-27 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | チオフェンおよびホスファチジルイノシトール3−キナーゼ(pi3k)阻害薬としてのその使用 |
WO2009111547A1 (en) * | 2008-03-04 | 2009-09-11 | Wyeth | 7h-pyrrolo[2,3-h]quinazoline compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis |
EP2444403A1 (en) * | 2008-04-18 | 2012-04-25 | Shionogi Co., Ltd. | Heterocyclic compound having inhibitory activity on PI3K |
US20110212053A1 (en) * | 2008-06-19 | 2011-09-01 | Dapeng Qian | Phosphatidylinositol 3 kinase inhibitors |
EP2168582A1 (en) | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines |
EP2168583A1 (en) | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
EP2356120B1 (en) * | 2008-09-30 | 2016-10-12 | Pfizer Inc. | Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions |
US8815891B2 (en) * | 2008-11-11 | 2014-08-26 | Je Il Pharmaceutical Co., Ltd. | Tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same |
US9492449B2 (en) | 2008-11-13 | 2016-11-15 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
AU2009313878B2 (en) | 2008-11-13 | 2016-01-07 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
US9495515B1 (en) | 2009-12-09 | 2016-11-15 | Veracyte, Inc. | Algorithms for disease diagnostics |
CN102395585A (zh) * | 2009-01-30 | 2012-03-28 | 米伦纽姆医药公司 | 杂芳基化合物和其作为pi3k抑制剂的用途 |
US9090601B2 (en) | 2009-01-30 | 2015-07-28 | Millennium Pharmaceuticals, Inc. | Thiazole derivatives |
BRPI1012333A2 (pt) | 2009-03-24 | 2016-03-29 | Gilead Calistoga Llc | atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso |
US8546409B2 (en) | 2009-04-20 | 2013-10-01 | Gilead Calistoga Llc | Methods of treatment for solid tumors |
AU2010243613B2 (en) * | 2009-04-30 | 2015-05-07 | Glaxo Group Limited | Oxazole substituted indazoles as PI3-kinase inhibitors |
CN102647987A (zh) | 2009-07-21 | 2012-08-22 | 吉里德卡利斯托加公司 | 使用pi3k抑制剂治疗肝脏障碍 |
SG179085A1 (en) * | 2009-09-09 | 2012-04-27 | Avila Therapeutics Inc | Pi3 kinase inhibitors and uses thereof |
KR20130098155A (ko) | 2010-04-16 | 2013-09-04 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린-함유 조합물 |
WO2012021611A1 (en) | 2010-08-11 | 2012-02-16 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
PE20140165A1 (es) | 2010-10-01 | 2014-02-26 | Bayer Ip Gmbh | Combinaciones que contienen n-(2-arilamino)arilsulfonamida |
EP2638043B1 (en) * | 2010-11-11 | 2017-06-07 | Bayer Intellectual Property GmbH | Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-c]quinolines |
WO2012062745A1 (en) * | 2010-11-11 | 2012-05-18 | Bayer Pharma Aktiengesellschaft | Alkoxy-substituted 2,3-dihydroimidazo[1,2-c]quinazolines |
UA113280C2 (xx) | 2010-11-11 | 2017-01-10 | АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ | |
EP2508525A1 (en) | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
JO3733B1 (ar) | 2011-04-05 | 2021-01-31 | Bayer Ip Gmbh | استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة |
BR112014021935A2 (pt) | 2012-03-05 | 2019-09-24 | Gilead Calistoga Llc | formas polimórficas de (s)-2(l-(9h-purin-6-ilamino)propil)-5-fluoro-3-fenilquinazolina-4(3h)ona |
WO2014186036A1 (en) | 2013-03-14 | 2014-11-20 | Allegro Diagnostics Corp. | Methods for evaluating copd status |
BR112015023203A8 (pt) | 2013-03-15 | 2018-01-23 | Constellation Pharmaceuticals Inc | métodos para tratamento de câncer, método para aumentar a eficiência de um tratamento de câncer, método para retardar e/ou prevenir o desenvolvimento de câncer, método para tratar um indivíduo com câncer, método para aumentar a sensibilidade para um agente de terapia para câncer, método para estender um período de sensibilidade e método para estender a duração da resposta para uma terapia para câncer. |
US11976329B2 (en) | 2013-03-15 | 2024-05-07 | Veracyte, Inc. | Methods and systems for detecting usual interstitial pneumonia |
EP2983669B1 (en) | 2013-04-08 | 2018-10-24 | Bayer Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas |
MY182082A (en) | 2013-05-01 | 2021-01-18 | Hoffmann La Roche | Biheteroaryl compounds and uses thereof |
WO2015027431A1 (en) | 2013-08-29 | 2015-03-05 | Merck Sharp & Dohme Corp. | 2,2-difluorodioxolo a2a receptor antagonists |
WO2015095605A1 (en) | 2013-12-20 | 2015-06-25 | Gilead Calistoga Llc | Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one |
NZ720867A (en) | 2013-12-20 | 2018-01-26 | Gilead Calistoga Llc | Process methods for phosphatidylinositol 3-kinase inhibitors |
BR112016028642A2 (pt) | 2014-06-13 | 2017-08-22 | Gilead Sciences Inc | composto, composição farmacêutica, método de tratamento de uma doença ou condição, método de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase, método de inibição de reações imunes ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, e, uso de um composto, de um sal, de um isômero ou de uma mistura farmaceuticamente aceitável do mesmo. |
EP3770274A1 (en) | 2014-11-05 | 2021-01-27 | Veracyte, Inc. | Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data |
EP3018127A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
EP3018131A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
MX2017011635A (es) | 2015-03-09 | 2018-02-09 | Bayer Pharma AG | Combinaciones que contienen 2,3-dihidroimidazo[1,2-c]quinazolina sustituida. |
CN105130997B (zh) * | 2015-09-25 | 2017-12-05 | 苏州明锐医药科技有限公司 | 一种库潘尼西的制备方法 |
CN105130998B (zh) * | 2015-09-25 | 2017-07-28 | 苏州立新制药有限公司 | 库潘尼西的制备方法 |
JP6935415B2 (ja) * | 2016-03-08 | 2021-09-15 | バイエル ファーマ アクチエンゲゼルシャフト | 2−アミノ−N−[7−メトキシ−2,3−ジヒドロイミダゾ−[1,2−c]キナゾリン−5−イル]ピリミジン−5−カルボキサミド類 |
EP3219329A1 (en) | 2016-03-17 | 2017-09-20 | Bayer Pharma Aktiengesellschaft | Combinations of copanlisib |
US10927417B2 (en) | 2016-07-08 | 2021-02-23 | Trustees Of Boston University | Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions |
CN109729716B (zh) | 2016-09-23 | 2022-03-15 | 拜耳制药股份公司 | Pi3k-抑制剂的组合产品 |
JP2020503289A (ja) | 2016-12-14 | 2020-01-30 | ターベダ セラピューティクス インコーポレイテッドTarveda Therapeutics,Inc. | Hsp90標的化コンジュゲート及びその製剤 |
EP3585437B1 (en) | 2017-02-24 | 2022-12-21 | Bayer Pharma Aktiengesellschaft | Combinations of copanlisib with anti-pd-1 antibody |
CA3068324A1 (en) | 2017-06-28 | 2019-01-03 | Bayer Consumer Care Ag | Combination of a pi3k-inhibitor with an androgen receptor antagonist |
MX2020002633A (es) | 2017-09-08 | 2020-07-13 | Bayer Consumer Care Ag | Formulaciones de copanlisib. |
EP3498266A1 (en) | 2017-12-15 | 2019-06-19 | Bayer Consumer Care AG | Formulations of copanlisib |
JP7394768B2 (ja) * | 2017-09-20 | 2023-12-08 | エイビーエム セラピューティックス コーポレイション | キナーゼ阻害剤としての環状イミノピリミジン誘導体 |
EP3694511A1 (en) | 2017-10-13 | 2020-08-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combination treatment of pancreatic cancer |
WO2019101871A1 (en) | 2017-11-23 | 2019-05-31 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | A new marker for predicting the sensitivity to pi3k inhibitors |
WO2019105734A1 (en) | 2017-11-28 | 2019-06-06 | Bayer Consumer Care Ag | Combinations of copanlisib |
WO2019105835A1 (en) | 2017-11-29 | 2019-06-06 | Bayer Consumer Care Ag | Combinations of copanlisib and anetumab ravtansine |
WO2019197269A1 (en) | 2018-04-11 | 2019-10-17 | Bayer Aktiengesellschaft | Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer |
WO2020020385A1 (zh) * | 2018-07-27 | 2020-01-30 | 上海翰森生物医药科技有限公司 | 含三并环类衍生物抑制剂、其制备方法和应用 |
CN109053554B (zh) * | 2018-08-01 | 2020-07-28 | 江苏八巨药业有限公司 | 一种使用催化剂合成3-乙酰吡啶的方法 |
US20210187134A1 (en) | 2018-08-28 | 2021-06-24 | Bayer As | Combination of pi3k-inhibitors and targeted thorium conjugates |
CA3116230A1 (en) | 2018-10-16 | 2020-04-23 | Bayer Aktiengesellschaft | Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds |
EP3877511A1 (en) | 2018-11-05 | 2021-09-15 | Iovance Biotherapeutics, Inc. | Expansion of tils utilizing akt pathway inhibitors |
US20220040324A1 (en) | 2018-12-21 | 2022-02-10 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
WO2020164997A1 (en) | 2019-02-12 | 2020-08-20 | Bayer Aktiengesellschaft | Combination of pi3k-inhibitors |
CN114621236A (zh) * | 2022-04-25 | 2022-06-14 | 河南湾流生物科技有限公司 | 一种喹啉类饲料添加剂的制备方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3644354A (en) * | 1968-09-16 | 1972-02-22 | Sandoz Ag | 5-substituted-2 3-dihydroimidazo(1 2-c)quinazolines |
US4287341A (en) | 1979-11-01 | 1981-09-01 | Pfizer Inc. | Alkoxy-substituted-6-chloro-quinazoline-2,4-diones |
CN1033644C (zh) * | 1993-01-02 | 1996-12-25 | 瑞安大药厂股份有限公司 | 3-取代甲基-2,3-二氢咪唑并[1,2-c]喹唑啉衍生物,其制备与用途 |
WO1996004923A1 (en) | 1994-08-12 | 1996-02-22 | Pro-Neuron, Inc. | Methods for treating sepsis or inflammatory diseases with oxypurine nucleosides |
WO1997027177A2 (en) * | 1996-01-29 | 1997-07-31 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Dihydropyridine-, pyridine-, benzopyran-4-one- and triazoloquinazoline derivatives, their preparation and their use as adenosine receptor antagonists |
US5932584A (en) * | 1997-05-06 | 1999-08-03 | National Science Council | Optically active 2,3-dihydroimidazo(1,2-C) quinazoline derivatives, the preparation and antihypertensive use thereof |
DE60144277D1 (de) | 2000-04-25 | 2011-05-05 | Icos Corp | Hemmer der menschlichen phosphatidyl-inositol-3-kinase delta |
AU5261001A (en) * | 2000-04-27 | 2001-11-12 | Imperial Cancer Research Technology Ltd | Condensed heteroaryl derivatives |
-
2003
- 2003-09-18 PT PT08075839T patent/PT2042504E/pt unknown
- 2003-09-18 BR BRPI0314830A patent/BRPI0314830B8/pt active IP Right Grant
- 2003-09-18 PL PL375935A patent/PL226562B1/pl unknown
- 2003-09-18 AU AU2003293310A patent/AU2003293310B2/en not_active Expired
- 2003-09-18 AT AT03788908T patent/ATE411996T1/de active
- 2003-09-18 PT PT03788908T patent/PT1549652E/pt unknown
- 2003-09-18 CN CNB038233673A patent/CN100384846C/zh not_active Expired - Lifetime
- 2003-09-18 DE DE60324296T patent/DE60324296D1/de not_active Expired - Lifetime
- 2003-09-18 EP EP03788908A patent/EP1549652B1/en not_active Expired - Lifetime
- 2003-09-18 ES ES03788908T patent/ES2312843T3/es not_active Expired - Lifetime
- 2003-09-18 DK DK03788908T patent/DK1549652T3/da active
- 2003-09-18 SI SI200332036T patent/SI2042504T1/sl unknown
- 2003-09-18 EP EP08075839A patent/EP2042504B1/en not_active Expired - Lifetime
- 2003-09-18 UA UAA200504176A patent/UA82205C2/uk unknown
- 2003-09-18 DK DK08075839.4T patent/DK2042504T3/da active
- 2003-09-18 KR KR1020057005434A patent/KR101059652B1/ko active IP Right Grant
- 2003-09-18 RU RU2005113165/04A patent/RU2326881C9/ru active
- 2003-09-18 MX MXPA05001808A patent/MXPA05001808A/es active IP Right Grant
- 2003-09-18 SI SI200331490T patent/SI1549652T1/sl unknown
- 2003-09-18 WO PCT/EP2003/010377 patent/WO2004029055A1/en active Application Filing
- 2003-09-18 AT AT08075839T patent/ATE511510T1/de active
- 2003-09-18 JP JP2004538935A patent/JP4790266B2/ja not_active Expired - Lifetime
- 2003-09-18 NZ NZ539062A patent/NZ539062A/en not_active IP Right Cessation
- 2003-09-18 ES ES08075839T patent/ES2367141T3/es not_active Expired - Lifetime
- 2003-09-18 US US10/527,376 patent/US7511041B2/en not_active Expired - Lifetime
- 2003-09-18 CA CA2499134A patent/CA2499134C/en not_active Expired - Lifetime
- 2003-09-29 UY UY28001A patent/UY28001A1/es active IP Right Grant
- 2003-09-29 PE PE2003000986A patent/PE20050089A1/es active IP Right Grant
- 2003-09-29 AR ARP030103542A patent/AR041426A1/es active IP Right Grant
- 2003-09-29 TW TW092126767A patent/TWI327570B/zh not_active IP Right Cessation
- 2003-09-29 MY MYPI20033701A patent/MY140756A/en unknown
-
2005
- 2005-02-14 IL IL166855A patent/IL166855A/en active IP Right Grant
- 2005-04-25 ZA ZA200503306A patent/ZA200503306B/en unknown
- 2005-04-27 HR HRP20050375AA patent/HRP20050375B1/hr not_active IP Right Cessation
- 2005-04-27 NO NO20052076A patent/NO331457B1/no not_active IP Right Cessation
- 2005-04-28 EC EC2005005768A patent/ECSP055768A/es unknown
- 2005-04-29 MA MA28247A patent/MA27483A1/fr unknown
-
2006
- 2006-04-19 HK HK06104675.8A patent/HK1084393A1/xx not_active IP Right Cessation
-
2009
- 2009-01-09 CY CY20091100017T patent/CY1109790T1/el unknown
- 2009-03-30 US US12/414,257 patent/US8129386B2/en not_active Expired - Lifetime
- 2009-07-01 AR ARP090102458A patent/AR072458A2/es not_active Application Discontinuation
-
2011
- 2011-02-07 EC EC2011005768A patent/ECSP11005768A/es unknown
- 2011-08-10 CY CY20111100771T patent/CY1112174T1/el unknown
-
2013
- 2013-12-04 HR HRP20131159A patent/HRP20131159B1/hr not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR041426A1 (es) | Derivados de azol-pirimidina condensados; uso del compuesto para la preparacion de medicamentos | |
PE20171341A1 (es) | Compuestos de pirazina para el tratamiento de enfermedades infecciosas | |
PE20221264A1 (es) | Inhibidores de egfr | |
AR074435A1 (es) | Derivados de 1,3-benzotiazol, medicamentos que los contienen y uso de los mismos en el tratamiento del cancer. | |
CO6231028A2 (es) | Compuestos y composiciones como inhibidores de la proteina quinasa | |
PE20181144A1 (es) | Derivados de heteroarilo como inhibidores de parp | |
EA201891463A1 (ru) | ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРАЗИН-4-ИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ (JAK) | |
AR102094A1 (es) | Inhibidores de proteínas kras con una mutación g12c | |
PE20141598A1 (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
AR053232A1 (es) | Derivados de piridina condensadas, composiciones farmaceuticas que los contienen y su empleo en la fabricacion de agentes terapeuticos antiinflamatorios y para el tratamiento de enfermedades relacionadas con el sistema inmunologico. | |
AR036035A1 (es) | Pirimidinas inhibidoras de cdk, su uso para preparar un medicamento y en forma de preparado farmaceutico, los medicamentos y las composiciones farmaceuticas que las contienen, el uso de estas composiciones en forma de preparado, y el uso de compuestos en calidad de productos intermedios para la sint | |
PE20050691A1 (es) | Proceso para preparar carboxamidas 2-aminotiazol-5-aromaticas como inhibidores de la cinasa | |
RU2013138717A (ru) | Конденсированные производные аминодигидротиазина, пригодные в качестве ингибиторов васе | |
AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
PE20191245A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim | |
PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
ATE463483T1 (de) | 6-substituierte isochinolinderivate als rock-1- inhibitoren | |
PE20070855A1 (es) | Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas | |
AR039540A1 (es) | Compuestos microbicidas con contenido de pirimidina o triazina | |
AR062937A1 (es) | Compuestos que modulan el receptor cb2 | |
TW200833686A (en) | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors | |
AR059622A1 (es) | Quinolonas utiles como inhibidores de la sintetasa del oxido nitrico inducibles | |
EA201592252A1 (ru) | 6,7-ДИГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИН-4(5H)-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ОТРИЦАТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ MGLUR2 | |
AR064318A1 (es) | Compuesto y composicion derivada de aril sulfamida, uso del compuesto y proceso para la preparacion del compuesto | |
AR040278A1 (es) | Ligandos del receptor de glucocorticoides para el tratamiento de trastornos metabolicos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |